GRI
GRI Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.48
+7.25%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +97.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- -45.5%
- EBIT
- -45.4%
- Net income
- -45.7%
- EPS
- —
- Free cash flow
- -18.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026